Reviva Pharmaceuticals Holdings, Inc. stock is down -28.96% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 November’s closed higher than October. In the last 5 Unusual Options Trades, there were 3 CALLs, 2 PUTs. 100% of analysts rate it a buy.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|29 Sep 13:48||20 Oct, 2023||5.00||17593|
|03 Oct 17:34||17 Nov, 2023||2.50||2138|
|30 Oct 16:14||19 Jan, 2024||7.50||606|
|30 Oct 16:27||17 Nov, 2023||5.50||456|
|02 Nov 13:57||17 Nov, 2023||10.00||381|
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia. RP1208 that is in pre-clinical development studies for depression and obesity.